Overview

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

Status:
Completed

Trial end date:
2011-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to determine if XPF-002 is safe and effective for the treatment of pain in subjects with Postherpetic Neuralgia

Phase:

Phase 2

Details

Lead Sponsor:

Xenon Pharmaceuticals Inc.